个人简介：
药学院博士生导师，紫江青年学者 主要从事领域包括开发可控型CRISPR系统用于DNA/RNA编辑和精准表观遗传学调控的研究，开发基于mRNA的CRISPR-RNA编辑工具用于遗传疾病的治疗研究和开发mRNA疫苗的研究，以及研究纳米药物递送体系的开发与其在肿瘤诊疗中的应用。研究兴趣为mRNA药物开发和利用化学生物学和mRNA技术来应对CRISPR技术生物应用面临的挑战，旨在推进CRISPR编辑工具在生物、临床研究中的广泛应用。目前以第一作者/共同第一作者身份在Nat. Commun，J. Am. Chem. Soc，Angew. Chem. Int. Ed，ACS Nano，Biomaterials等领域高水平期刊上发表10篇论文，并参与第二版《Encyclopedia of Cell Biology》的撰写。
联系方式：yxu@pharm.ecnu.edu.cn
教育经历：
2019.08 - 2023.08 凯斯西储大学 哲学博士 专业：化学 指导老师：Fu-Sen Liang教授
2016.09 – 2019.06 中国科学院大学理学硕士专业：纳米科学与技术 指导老师：聂广军研究员
2016.09 – 2019.01 哥本哈根大学 理学硕士 专业：纳米科学与技术 研究领域：Ken-Howard 教授
2012.09 – 2016.06青岛大学理学学士 专业：化学
工作经历：
2024.09-至今 华东师范大学，紫江青年学者
2023.08-至今 宾夕法尼亚大学，博士后，从事CRISP介导的RNA编辑研究和mRNA疫苗开发研究，合作导师：Dr. Drew Weissman（2023诺贝尔生理医学奖获得者）
研究方向：
1.基于mRNA的CRISPR-RNA表观遗传学编辑研究
2.基于mRNA的CRISPR-RNA编辑用于遗传疾病的治疗研究
3.mRNA药物开发，包括传染性疾病和肿瘤疫苗开发、蛋白替换疗法等
招生与培养：
实验室招生专业：Welcome to our lab (lilab-ecust.cn)
1. 药学学术博士、硕士（核酸药物设计、药物化学）
2. 生物与医药工程工程博士、硕士（药物递送、制药工程、生物技术工程）
学术成果：
1.Y Xu, Y Wang, FS Liang*. Site‐Specific m6A Erasing via Conditionally Stabilized CRISPR Cas13b Editor. Angew. Chem.Int. Ed. 2023,62, e2023092
2.Y Xu, N Tian, H Shi, C Zhou, Y Wang, FS Liang*. A Split CRISPR/Cas13b System for Conditional RNA Regulation and Editing. J. Am. Chem. Soc. 2023, 145 (9), 5561-5569.
3.Y Xu+, Y Wang+, FS Liang* A CRISPR-based Strategy for Temporally Controlled Site-Specific Editing of RNA Modifications. Bio-protocol, 2023, 13(3): e4607.
4.Y Xu, FS Liang*. On demand CRISPR-mediated RNA N6-methyladenosine editing. Genes & Diseases, 2022, 9 (6), 1389-1390.
5.H Shi+, Y Xu+, N Tian, M Yang, FS Liang*. Inducible and reversible RNA N6-methyladenosine editing. Nat. Commun, 2022, 13(1), 1958.
6.W Zhao+, Y Xu+, Y Wang, D Gao, J King, Y Xu, FS Liang*. Investigating crosstalk between H3K27 acetylation and H3K4 trimethylation in CRISPR/dCas-based epigenome editing and gene activation. Scientific reports, 2021, 11 (1), 15912.
7.X. Han+, Y. Xu+, M. Geranpayehvaghei, G.J. Anderson, Y. Li*, G. Nie*, Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors. Biomaterials, 2020, 232: 119745.
8.X. Han+, K. Cheng+, Y. Xu+, Y. Wang, H. Min, Y. Zhang, X. Zhao, R. Zhao, G.J. Anderson, L. Ren, G. Nie*, Y. Li*. Modularly designed peptide nanoprodrug augments antitumor immunity of PD-L1 checkpoint blockade by targeting indoleamine 2, 3-dioxygenase. J. Am. Chem. Soc., 2020, 142: 2490-2496.
9.Y Xu+, X Han+, Y Li*, H Min, X Zhao, Y Zhang, Y Qi, J Shi, S Qi, Y Bao*, G Nie*. Sulforaphane mediates glutathione depletion via polymeric nanoparticles to restore cisplatin chemosensitivity. ACS Nano, 2019, 13 (11), 13445-13455.
10.X. Han+, Y. Xu+, Y. Li*, X. Zhao, Y. Zhang, H. Min, G.J. Anderson, Y. Zhao*, G. Nie*, An extendable star-like nanoplatform for functional and anatomical imaging-guided photothermal oncotherapy. ACS Nano, 2019, 13(4): 4379-4391.
11.X. Han+, J. Xu+, Y Xu, MG. Alameh, L. Xue, N. Gong, R. El-Mayta, R. Palanki, C. Warzecha, G. Zhao, A. Vaughan, J. Wilson, D. Weissman, M. Mitchell*, In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors. Nat. Commun., 2024, 15:1762.
12.X. Han+, MG. Alameh+, K. Butowska, JJ. Knox, K. Lundgreen, M. Ghattas, N. Gong, L. Xue, Y. Xu, M. Lavertu, P. Bates, J. Xu, G. Nie, Y. Zhong, D. Weissman*, M. Mitchell*, LAdjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotech., 2023, 18, 1105-1114.
13.FS Liang*, Y Xu, RNA Epigenetics and Epitranscriptomics: The Emerging Gene Regulatory Landscape Through RNA Modifications. Encyclopedia of Cell Biology, Second Edition (CLB2), 2023, vol. 1, pp. 580-591.
14.H. Min, Y. Qi, Y. Chen, Y. Zhang, X. Han, Y. Xu, Y. Liu, J. Hu, H. Liu, Y. Li*, G. Nie*. Synthesis and imaging of biocompatible graphdiyne quantum dots. ACS Appl. Mater. Interfaces, 2019, 11: 32798.
15.H. Min, J Wang, Y. Qi，Y. Zhang, X. Han, Y. Xu, Y. Li, L. Chen, K. Cheng, G. Liu, N. Yang, Y. Li*, G. Nie*. Biomimetic metal–organic framework nanoparticles for cooperative combination of anti-angiogenesis and photodynamic therapy for enhanced efficacy. Adv. Mater., 2019, 31 (15), 1808200.
16.X. Han, Y. Li*, Y. Xu, X. Zhao, Y. Zhang, X. Yang, Y. Wang, R. Zhao, G.J. Anderson, Y. Zhao*, G. Nie*, Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem, Nat. Commun., 2018, 9(1): 3390.
